Stockreport

Summit Therapeutics: PDUFA Coming, But Is It Good Enough? (Rating Upgrade) [Seeking Alpha]

Summit Therapeutics Inc.  (SMMT) 
Last summit therapeutics inc. earnings: 6/12 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: summitplc.com/investors/investor-centre
PDF SMMT's lead asset, ivonescimab, faces an FDA decision for EGFR-mutant NSCLC by November 2026, with PFS benefit but uncertain overall survival impact. Liquidity is sol [Read more]